Literature DB >> 33974243

Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis.

Stefano Piaserico1, Andrea Conti2, Francesco Messina3, Alberto Meneguzzo3, Giulia Odorici2, Francesco Bellinato4, Paolo Gisondi4.   

Abstract

Entities:  

Year:  2021        PMID： 33974243     DOI： 10.1007/s40259-021-00485-8

Source DB:  PubMed          Journal:  BioDrugs        ISSN： 1173-8804            Impact factor:   5.807


× No keyword cloud information.
  7 in total

1.  Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.

Authors:  A Egeberg; M B Ottosen; R Gniadecki; S Broesby-Olsen; T N Dam; L E Bryld; M K Rasmussen; L Skov
Journal:  Br J Dermatol       Date:  2018-01-09       Impact factor: 9.302

2.  Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice.

Authors:  Ambre Lauret; Anna Moltó; Vered Abitbol; Loriane Gutermann; Ornella Conort; François Chast; Claire Goulvestre; Claire Le Jeunne; Stanislas Chaussade; Christian Roux; Frédéric Batteux; Maxime Dougados; Yannick Allanore; Jérôme Avouac
Journal:  Semin Arthritis Rheum       Date:  2020-02-19       Impact factor: 5.532

Review 3.  Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.

Authors:  Kelly A Reynolds; Deeti J Pithadia; Erica B Lee; Wilson Liao; Jashin J Wu
Journal:  Am J Clin Dermatol       Date:  2020-08       Impact factor: 7.403

4.  Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.

Authors:  S K Mahil; M Yates; S M Langan; Z Z N Yiu; T Tsakok; N Dand; K J Mason; H McAteer; F Meynell; B Coker; A Vincent; D Urmston; A Vesty; J Kelly; C Lancelot; L Moorhead; H Bachelez; I N Bruce; F Capon; C R Contreras; A P Cope; C De La Cruz; P Di Meglio; P Gisondi; K Hyrich; D Jullien; J Lambert; H Marzo-Ortega; I McInnes; L Naldi; S Norton; L Puig; R Sengupta; P Spuls; T Torres; R B Warren; H Waweru; J Weinman; C E M Griffiths; J N Barker; M A Brown; J B Galloway; C H Smith
Journal:  Br J Dermatol       Date:  2021-03-09       Impact factor: 11.113

5.  The nocebo effect of drugs.

Authors:  Sara Planès; Céline Villier; Michel Mallaret
Journal:  Pharmacol Res Perspect       Date:  2016-03-17

6.  Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.

Authors:  S Gerdes; D Thaçi; C E M Griffiths; P Arenberger; J Poetzl; G Wuerth; M Afonso; H Woehling
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-02       Impact factor: 6.166

Review 7.  Immunogenicity of TNF-Inhibitors.

Authors:  Sadaf Atiqi; Femke Hooijberg; Floris C Loeff; Theo Rispens; Gerrit J Wolbink
Journal:  Front Immunol       Date:  2020-02-26       Impact factor: 7.561
  7 in total
  3 in total

1.  Switching Among Biosimilars: A Review of Clinical Evidence.

Authors:  Eleonora Allocati; Brian Godman; Marco Gobbi; Silvio Garattini; Rita Banzi
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

2.  Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.

Authors:  Hillel P Cohen; Sohaib Hachaichi; Wolfram Bodenmueller; Tore K Kvien; Silvio Danese; Andrew Blauvelt
Journal:  BioDrugs       Date:  2022-07-26       Impact factor: 7.744

3.  Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.

Authors:  Giovanni Damiani; Giulia Odorici; Alessia Pacifico; Aldo Morrone; Rosalynn R Z Conic; Tima Davidson; Abdulla Watad; Paolo D M Pigatto; Delia Colombo; Piergiorgio Malagoli; Marco Fiore
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.